Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

146P - Prognostic impact of HER2-low expression according to the oncotype Dx recurrence score in hormone receptor-positive early breast cancer

Date

16 Sep 2021

Session

ePoster Display

Presenters

Raz Mutai

Citation

Annals of Oncology (2021) 32 (suppl_5): S407-S446. 10.1016/annonc/annonc687

Authors

R. Mutai1, T. Barkan1, A. Moore1, M. Sarfaty1, S. Stemmer1, T. Shohat1, R. Yerushlami1, H. Goldvaser2

Author affiliations

  • 1 Oncology, Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, 4941492 - Petah Tikva/IL
  • 2 Oncology, The integrated Oncology Institute Shaare Zedek Medical Center,, 9103102 - Jerusalem/IL
More

Abstract 146P

Background

The prognostic role of human epidermal growth factor receptor 2 (HER2) low expression in estrogen receptor (ER)-positive, HER2-negative breast cancer is not well described. The aim of this study is to compare disease characteristics and outcomes between HER2-low to HER2-0, in early-stage luminal disease.

Methods

A single center retrospective study comprising all women with ER-positive, HER2-negative early breast cancer, for whom an Oncotype DX test was performed between 2005-2012. Women were grouped to HER2-low (immunohistochemistry +1 or +2 and in situ hybridization not amplified) or HER2-0. Clinico-pathological features including tumor size, nodal involvement, grade, ki-67, intensity of hormone receptors expression, histology subtype lympho-vascular and perineural invasion and Oncotype recurrence score (RS) were collected. Data on overall survival (OS), disease-free survival (DFS) and distant DFS (DDFS) were also evaluated. Differences by HER2 expression were investigated.

Results

608 women were included, of which 304 women had HER2-0 and 304 had HER2-low disease. Lobular subtype was more common in HER-0 compared to HER2-low disease (17% vs. 8%, p=0.005). All other characteristics did not differ between the two groups. At a median follow up of 10.3 years, OS, DFS and DDFS were similar for the whole population. Analyses by genomic risk showed comparable outcomes for women with low genomic risk (RS≤25), but for women with high genomic risk (RS>25), HER2-low was associated with significantly favorable OS (HR=0.31, 95% CI 0.11-0.78, p=0.01), DFS (HR= 0.40, 95% CI 0.20-0.82; p=0.01) and DDFS (HR=0.26, 95% CI 0.11-0.63, P=0.002).

Conclusions

The prognostic impact of HER2-low expression in early-stage luminal disease varies across the genomic risk, with significant favorable outcomes of HER2-low compared to HER2-0 in women with high genomic risk. As other prognostic characteristics were comparable between HER2-low and HER2-0, our findings may be consistent with a novel prognostic feature for this population.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

A. Moore: Other, Personal, Other, honorarium: Merck; Other, Personal, Other, honorarium: Roche. M. Sarfaty: Other, Personal, Advisory Board: Merck; Other, Personal, Advisory Board: Novartis; Other, Personal, Advisory Board: Roche. S. Stemmer: Other, Personal, Research Grant: Teva; Other, Personal, Research Grant: Clovis Oncology; Other, Personal, Research Grant: AstraZeneca; Other, Personal, Research Grant: BioPharma; Other, Personal, Research Grant: Puma Biotechnology; Other, Personal, Research Grant: Lilly; Other, Personal, Research Grant: Bristol Myers Squibb; Other, Personal, Research Grant: Roche; Other, Personal, Research Grant: MSD; Other, Personal, Research Grant: Moderna Therapeutics; Other, Personal, Research Grant: Exelixis; Other, Personal, Research Grant: Rafael Pharmaceuticals; Other, Personal, Research Grant: CTG Pharma; Other, Personal, Research Grant: Syncore; Other, Personal, Research Grant: Can-Fite BioPharma. R. Yerushlami: Other, Personal, Invited Speaker: Roche; Other, Personal, Invited Speaker: Teva; Other, Personal, Invited Speaker: MSD; Other, Personal, Invited Speaker: AstraZeneca; Other, Personal, Invited Speaker: Novartis; Other, Personal, Invited Speaker: Medison; Other, Personal, Advisory Role: Pfizer . H. Goldvaser: Other, Personal, Other, honorarium: Roche; Other, Personal, Other, honorarium: Pfizer; Other, Personal, Invited Speaker, honorarium: Novartis; Other, Personal, Other, honorarium: Oncotest. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.